Assessing heterogeneity of electronic health‐care databases: A case study of background incidence rates of venous thromboembolism

Author:

Russek Martin1,Quinten Chantal1,de Jong Valentijn M. T.12,Cohet Catherine1,Kurz Xavier1ORCID

Affiliation:

1. Data Analytics and Methods Task Force European Medicines Agency Amsterdam The Netherlands

2. Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht The Netherlands

Abstract

AbstractPurposeHeterogeneous results from multi‐database studies have been observed, for example, in the context of generating background incidence rates (IRs) for adverse events of special interest for SARS‐CoV‐2 vaccines. In this study, we aimed to explore different between‐database sources of heterogeneity influencing the estimated background IR of venous thromboembolism (VTE).MethodsThrough forest plots and random‐effects models, we performed a qualitative and quantitative assessment of heterogeneity of VTE background IR derived from 11 databases from 6 European countries, using age and gender stratified background IR for the years 2017–2019 estimated in two studies. Sensitivity analyses were performed to assess the impact of selection criteria on the variability of the reported IR.ResultsA total of 54 257 284 subjects were included in this study. Age–gender pooled VTE IR varied from 5 to 421/100 000 person‐years and IR increased with increasing age for both genders. Wide confidence intervals (CIs) demonstrated considerable within‐data‐source heterogeneity. Selecting databases with similar characteristics had only a minor impact on the variability as shown in forest plots and the magnitude of the I2 statistic, which remained large. Solely including databases with primary care and hospital data resulted in a noticeable decrease in heterogeneity.ConclusionsLarge variability in IR between data sources and within age group and gender strata warrants the need for stratification and limits the feasibility of a meaningful pooled estimate. A more detailed knowledge of the data characteristics, operationalisation of case definitions and cohort population might support an informed choice of the adequate databases to calculate reliable estimates.

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference38 articles.

1. Big data in healthcare: management, analysis and future prospects

2. European Medicines Agencies Network Strategy to 2025.European Medicines Agency.2020. Accessed August 8 2022https://www.ema.europa.eu/en/documents/other/european‐medicines‐agencies‐network‐strategy‐2025‐protecting‐public‐health‐time‐rapid‐change_en.pdf

3. Framework for FDA's Real‐World Evidence Program.U.S. Food and Drug Administration.2018. Accessed August 8 2022https://www.fda.gov/media/120060/download

4. Data Analysis and Real World Interrogation Network (DARWIN EU).European Medicines Agency. Accessed August 8 2022https://www.ema.europa.eu/en/about‐us/how‐we‐work/big‐data/data‐analysis‐real‐world‐interrogation‐network‐darwin‐eu

5. ENCePP.The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology (Revision 10). Accessed August 8 2022https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3